학술논문

Tafasitamab in Combination with a CD20xCD3 Bispecific T-Cell Engager Significantly Prolongs Survival in Preclinical Lymphoma Models
Document Type
Journal
Source
BLOOD; NOV 2 2023, 142 3p. Supplement: 1
Subject
Language
English
ISSN
15280020